Masimo Co. (NASDAQ:MASI) Expected to Announce Earnings of $0.71 Per Share

Wall Street brokerages forecast that Masimo Co. (NASDAQ:MASI) will post $0.71 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Masimo’s earnings. The lowest EPS estimate is $0.70 and the highest is $0.72. Masimo also reported earnings per share of $0.71 in the same quarter last year. The business is scheduled to announce its next quarterly earnings report on Wednesday, October 30th.

On average, analysts expect that Masimo will report full year earnings of $3.15 per share for the current year, with EPS estimates ranging from $3.14 to $3.16. For the next financial year, analysts anticipate that the business will post earnings of $3.62 per share, with EPS estimates ranging from $3.53 to $3.77. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Masimo.

Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The company had revenue of $229.60 million for the quarter, compared to analyst estimates of $222.46 million. Masimo had a return on equity of 18.18% and a net margin of 22.15%. Masimo’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.73 earnings per share.

Several brokerages have recently issued reports on MASI. UBS Group upped their price objective on Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 14th. BTIG Research restated a “hold” rating on shares of Masimo in a research report on Thursday. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $153.00 price objective on the stock in a research report on Wednesday, May 8th. Finally, Stifel Nicolaus upped their price objective on Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $159.25.

In related news, EVP Anand Sampath sold 30,000 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $142.39, for a total transaction of $4,271,700.00. Following the transaction, the executive vice president now directly owns 27,518 shares in the company, valued at $3,918,288.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Yongsam Lee sold 258 shares of the stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $145.00, for a total value of $37,410.00. Following the transaction, the executive vice president now owns 73,736 shares in the company, valued at $10,691,720. The disclosure for this sale can be found here. Insiders sold 255,075 shares of company stock worth $38,222,741 over the last 90 days. Company insiders own 11.50% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. purchased a new position in Masimo during the second quarter worth about $31,000. FinTrust Capital Advisors LLC purchased a new position in Masimo during the first quarter worth about $61,000. Valeo Financial Advisors LLC purchased a new position in Masimo during the first quarter worth about $69,000. NEXT Financial Group Inc lifted its position in Masimo by 172.0% during the second quarter. NEXT Financial Group Inc now owns 544 shares of the medical equipment provider’s stock worth $81,000 after buying an additional 344 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in Masimo during the first quarter worth about $92,000. Hedge funds and other institutional investors own 82.80% of the company’s stock.

Masimo stock traded down $2.24 during trading hours on Friday, hitting $151.51. The stock had a trading volume of 384,852 shares, compared to its average volume of 333,405. Masimo has a 1-year low of $98.23 and a 1-year high of $160.25. The firm has a fifty day simple moving average of $150.41. The company has a market cap of $8.42 billion, a PE ratio of 50.00, a price-to-earnings-growth ratio of 3.15 and a beta of 1.14.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Recommended Story: What is a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.